1. Grundy SM. George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. British Medical Journal May 28, 2001
2. Ravnskov U. The Cholesterol Myths. New Trends publishing, Washington DC 2000.
3. Uffe Ravnskov author of The Cholesterol Myths New Cholesterol Guidelines for Converting Healthy People into Patients, dec. 2003
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285: 2486-2496.
5. Bradford R H, Shear C L, Chremos A N, Dujovne C A, Franklin F A, Grillo R B, Higgins J, Langendorfer A, Nash D T, Pool J L, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991; 151: 43-49.
6. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL, Cholesterol-Lowering Drugs are Less Effective in Reality than in Trials American Journal of Medicine December 2002;113:625-629
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Common Cholesterol Drug Lowers Cholesterol but Not Death Rate JAMA December 18, 2002;288:1998-3007,3042-3044
8. Matthias Rath M.D. and Linus Pauling Ph.D A Unified Theory of Human Cardiovascular Disease Leading the Way to the Abolition of This Disease as a Cause for Human Mortality
9. Peter H. Langsjoen, Cholesterol Drugs Actually Cause Heart Disease, Red Flags Daily July 10, 2003
10. Medical Research Council/British Heart Foundation Heart Protection Study.Press release. Life-saver: World’s largest cholesterol-lowering trial reveals massive benefits for high-risk patients. Available at www.ctsu.ox.ac.uk/~hps/pr.shtml.
11. Insulin Resistance Common in Patients with Health Disorders, Diabetes October, 1998;47:1643-1649.
12. Wierzbicki AS; Lumb PJ; Semra Y; Chik G; Christ ER; Crook MA. Atorvastatin compared with simvastatin based therapies in the management of severe familial hyperlipidaemias. Qjm, 1999;92(7):38794.
13. Bradford RH; Shear CL; Chremos AN; Dujovne C; Downton M; Franklin FA; et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine, 1991;151(1):439.
14. Chang, J, Green, L. Food and Drug Administration Memorandum. United States Department of Human and Health Services, May 1, 2000.
15. Physicians’ Desk Reference, 54th Edition. Montvale, N.J.: Medical Economics Company, 2000.
16. Cohen, JS. Adverse Drug Reactions: Effective Low-Dose Therapies for Older Patients. Geriatrics, Feb. 2000; 55(2):54-64.
17. Cohen, JS. Over Dose: The Case Against The Drug Companies. Tarcher/Putnam, New York: October 2001. Chapters cited include Chapter 5 “How the Drug Companies’ Policies Harm Women;” Chapter 6 “Why 50-75% of People Quit Taking Their Cholesterol-Lowering Medications;” Chapter 8 “Why Seniors Are at the Greatest Risk;” Chapter 14 “How You Can Avoid Side Effects and Use Medications Safely;” as well as chapters on the FDA, drug companies, and many other top-selling drugs.
18. American Medical Association Council on Ethical and Judicial Affairs. Code of Medical Ethics, 1998-1999 Edition. American Medical Association, Chicago, IL.
19. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multipledose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMGCoA reductase, in healthy subjects. Clinical Pharmacology and Therapeutics, 1996; 60(6):68795.
20. Abookire, SA, et al. Using and monitoring of statin lipid-lowering drugs…. Archives of Internal Medicine, Jan. 8, 2001; 161: 53-58.
21. Merck and Company. Nonprescription Mevacor. FDA Advisory Committee Background Information, FDA Website, June 2000: www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b1b.pdf.
22. Bristol-Myers Squibb. Advisory Committee Meeting Briefing Book for the Rx to OTC Switch of Pravachol (Pravastatin Sodium). Joint Meeting of Nonprescription Drugs Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee, 2000: www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b2a_part1.pdf.
23. Langsjoen PH. The clinical use of HMG Co-A reductase inhibitors (statins) and the associated depletion of the essential co-factor coenzyme Q10: a review of pertinent human and animal data. http://www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-02-Exhibit_A-vol1.pdf
24. Eleanor Laise. The Lipitor Dilemma, Smart Money: The Wall Street Journal Magazine of Personal Business, November 2003.
25. Langsjoen PH. The clinical use of HMG Co-A reductase inhibitors (statins) and the associated depletion of the essential co-factor coenzyme Q10: a review of pertinent human and animal data. http://www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-02-Exhibit_A-vol1.pdf
26. Sandra G Boodman. Statins’ Nerve Problems. Washington Post, September 3, 2002.
27. Gina Kolata. Study of Two Cholesterol Drugs Finds One Halts Heart Disease. The New York Times, November 13, 2003.
28. Extra-Low Cholesterol, The New York Times, March 10, 2003
29. Rob Stein. Striking Benefits Found in Ultra-Low Cholesterol, The Washington Post, March 9, 2004
30. Scott Hensley. The Statin Dilemma: How Sluggish Sales Hurt Merck, Pfizer. The Wall Street Journal, July 25, 2003.
31. John O’Neil. Treatments: Statins and Diabetes: New Advice. New York Times, April 20, 2004.